Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewKynurenic acid sodium salt is a sodium salt of kynurenic acid (Cat. No. 0223), a broad spectrum EAA antagonist.
Kynurenic acid sodium salt is also offered as part of the Tocriscreen 2.0 Max. Find out more about compound libraries available from Tocris.
M. Wt | 211.15 |
Formula | C10H6NNaO3 |
Storage | Desiccate at RT |
Purity | ≥98% (HPLC) |
CAS Number | 2439-02-3 |
PubChem ID | 52974250 |
InChI Key | RCAZGXKUQDXSSK-UHFFFAOYSA-M |
Smiles | [Na+].OC1=CC(=NC2=CC=CC=C12)C([O-])=O |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solvent | Max Conc. mg/mL | Max Conc. mM | |
---|---|---|---|
Solubility | |||
water | 21.11 | 100 | |
DMSO | 10.56 | 50 |
The following data is based on the product molecular weight 211.15. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 4.74 mL | 23.68 mL | 47.36 mL |
5 mM | 0.95 mL | 4.74 mL | 9.47 mL |
10 mM | 0.47 mL | 2.37 mL | 4.74 mL |
50 mM | 0.09 mL | 0.47 mL | 0.95 mL |
References are publications that support the biological activity of the product.
Perkins and Stone (1982) An iontophoretic investigation of the actions of convulsant kynurenines and their interaction with the endogenous excitant quinolinic acid. Brain Res. 247 184 PMID: 6215086
Pittaluga et al (1997) The 'kynurenate test', a biochemical assay for putative cognition enhancers. J.Pharmacol.Exp.Ther. 283 82 PMID: 9336311
Wang et al (2006) Kynurenic acid as a ligand for orphan G protein-coupled receptor GPR35. J.Biol.Chem. 281 22021 PMID: 16754668
Stone and Burton (1988) NMDA receptors and ligands in the vertebrate CNS. Progr.Neurobiol. 30 333 PMID: 2830636
If you know of a relevant reference for Kynurenic acid sodium salt, please let us know.
Keywords: Kynurenic acid sodium salt, Kynurenic acid sodium salt supplier, Broad, spectrum, EAA, antagonists, Glutamate, Ionotropic, Non-Selective, iGluR, Receptors, mGlur, Metabotropic, Non-selective, GPR35, 3694, Tocris Bioscience
Citations are publications that use Tocris products.
Currently there are no citations for Kynurenic acid sodium salt. Do you know of a great paper that uses Kynurenic acid sodium salt from Tocris? Please let us know.
There are currently no reviews for this product. Be the first to review Kynurenic acid sodium salt and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.
Peripheral sensitization is the reduction in the threshold of excitability of sensory neurons that results in an augmented response to a given external stimulus. This poster outlines the excitatory and inhibitory signaling pathways involved in modulation of peripheral sensitization. The role of ion channels, GPCRs, neurotrophins, and cytokines in sensory neurons are also described.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.